Aims: Gastric pyloric gland adenomas (PGAs) are rare epithelial polyps that are found more commonly in autoimmune atrophic gastritis and familial adenomatous polyposis (FAP). Little is known about the morphology and genetics of PGAs in FAP. PGAs in FAP are studied morphologically and genetically. Findings in FAP-associated PGAs are compared to sporadic PGAs and related lesions such as oxyntic gland adenoma (OGA) to increase our understanding of these rare polyps. Methods and results: Seven PGAs and 18 fundic gland polyps (FGPs) from FAP patients were collected. KRAS and GNAS mutations were determined in six PGAs and 18 FGPs. Immunohistochemistry was applied on five PGAs to provide further confirmation of the histological subtypes and genetic alterations. Morphology of all PGAs was studied and compared to literature on sporadic PGAs and related lesions. All successfully sequenced PGAs (six of six) carried GNAS mutations and half of the successfully sequenced PGAs carried a KRAS mutation (three of six). Nuclear b-catenin was seen only in one PGA with focal highgrade dysplasia. Morphologically, PGAs in FAP showed overlapping features with OGA. Conclusion: Familial adenomatous polyposis-associated PGAs have a similar genetic background as sporadic PGAs, i.e. KRAS and GNAS mutation. Based on morphological findings in FAP associated PGAs, it is hypothesized that PGAs and OGAs are closely related lesions.
Introduction
Gastric pyloric gland adenomas (PGAs) are rare polyps composed of a proliferation of pyloric glandlike epithelium with low columnar cells with typical pale or 'ground glass' cytoplasm. PGAs can be found throughout the gastrointestinal tract, but are seen most often in the stomach. Sporadic gastric PGAs are associated with autoimmune atrophic gastritis 1 and, as this is more prevalent in females, gastric PGAs are more frequent in elderly female patients. It has been estimated that 2.7% of gastric polyps are PGAs. 2 In addition, PGAs were described recently as a novel manifestation of familial adenomatous polyposis (FAP), occurring in 6% of these patients. 3 Immunohistochemistry of sporadic PGAs shows mucin (MUC) expression typical for pyloric gland differentiation, confirming the histological classification. The pyloric gland type mucin MUC6 was reported initially as positive in the deeper pyloric type glands, while MUC5AC -a surface gastric foveolar type mucin -was believed initially to be positive in the surface epithelium of these polyps. 4 More recently, co-labelling of MUC6 and MUC5AC has been noted in some of these lesions. 5 Genetic analysis showed GNAS mutations in 63% of sporadic PGAs but not in sporadic gastric foveolar and intestinal adenomas. 6 In contrast to sporadic PGAs, PGAs in FAP patients arise in pristine oxyntic mucosa wholly lacking gastritis, at least in a North American population. 3 Little is known about the morphological, immunohistochemical and genetic characteristics of PGAs in FAP. Only one previous study has analysed six FAP-associated upper gastrointestinal PGAs, concluding that FAP-associated and sporadic PGAs of the upper gastrointestinal tract show common genetic features, including GNAS, KRAS and APC mutations. 7 In this study we analyse seven PGAs and 18 fundic gland polyps (FGP) from FAP patients for mutations in KRAS and GNAS using a highly sensitive pyrosequencing technique. Also, immunohistochemistry is applied to provide further confirmation of the histological subtypes and genetic alteration, and FAP-associated PGAs are compared to existing literature on sporadic PGAs and related lesions such as oxyntic gland adenoma (OGA).
Materials and method
A computer search of the Johns Hopkins Department of Pathology Archives for 'Pyloric Gland Adenoma' and 'Fundic Gland Polyp AND Polyposis' was performed and cross-referenced to the Johns Hopkins Polyposis Registry for FAP patients. From each patient with a PGA in this study at least one FGP was included. In addition, a number of FGPs from FAP patients without PGAs were obtained. In total, seven PGAs and 18 FGPs were included ( Table 1) . The corresponding haematoxylin and eosin (H&E) slides of the polyps/biopsies were reviewed histologically by expert gastrointestinal pathologists (E.A.M., G.J.A.O., L.D.W. and L.A.A.B.) to confirm the diagnosis and to mark the area for DNA extraction. The study was performed in accordance with local medical ethical guidelines.
D N A E X T R A C T I O N
Formalin-fixed paraffin-embedded (FFPE) blocks of polyps and normal tissue were sectioned to slides (10 lm thick). Tissue was deparaffinized and the region of interest scraped off with a fine sterilized needle. DNA was extracted using the QIAamp DNA FFPE Tissue Kit (Qiagen, Gaithersburg, MD, USA) and eluted in a final volume of 30 ll Tris-acetate-EDTA (TAE) buffer. Extraction was performed in an ultraviolet (UV) hood to prevent DNA contamination. Polymerase chain reaction (PCR) was performed with a HotStarTaq DNA polymerase kit (Qiagen). PCR reactions of 25 ll contained 91 reaction buffer, 0.8 units of HotStarTaq DNA polymerase, 0.2 mM dNTPs (dATP, dGTP, dCTP, dTTP), 0.2 mM of each primer and 5 ll of genomic DNA. The initial denaturation at 95°C for 15 min was followed by DNA amplification cycles (60 cycles for KRAS, 80 cycles for GNAS; 95°C for 20 s, 53°C for 30 s and 72°C for 20 s with a final extension step of 72°C for 5 min). A negative control was included in each run.
The GNAS and KRAS amplicons were sequenced on the Pyromark Q24 (Qiagen) and Pyromark Q24 Vacuum Prep Workstation with Pyromark Gold reagents (Qiagen), streptavidin sepharose high performance (GE Healthcare Life Sciences, Pittsburgh, PA, USA), and the sequencing primer (GNAS 5 0 -TTT GTT TCA GGA CCT GCT TCG C-3 0 ; KRAS 5 0 -TGT GGT AGT TGG AGC T) using the Pyromark Q24 user manual's protocol. A negative control and water sample were included in each run.
I M M U N O H I S T O C H E M I S T R Y
Immunohistochemistry of MUC2, MUC5AC, MUC6, CDX2, Ki67, p53 and b-catenin was performed as described previously. 4, 8 The following antibodies were used: p53 (DO-7 + BP53-12, 1:2,000; Thermoscientific, Pittsburgh, PA, USA), b-catenin (clone 14 1:5000; BD Transduction Laboratories, San Jose, CA, USA), MUC2 (Ccp58, 1:500; Novocastra, Newcastle, UK), MUC5AC (CLH2, 1:100; Novocastra), MUC6 (CLH5, 1:50; Novocastra), CDX-2 (clone EPR2764Y; Immunologic, Duiven, the Netherlands) Ki 67 (MIB-1, 1:100; Immunotech, Marseille, France).
In brief, 4-lm sections were deparaffinized in xylene and endogenous peroxidase was blocked in 0.3% H 2 O 2 (Merck, Branchburg, NJ, USA) in methanol. Antigen retrieval was performed by cooking for 20 min in 10/mM TAE buffer. A blocking step was performed with 5% normal goat serum in phosphatebuffered saline (PBS) for 10 min. Next, the primary antibody was incubated for 1 h at room temperature (p53) or overnight at 4°C (MUC2, MUC5AC, MUC6, CDX2, Ki67 and b-catenin). Staining of the antibodies was performed with the poly-horseradish peroxidase 
Results

H I S T O L O G Y
The PGA diagnosis was confirmed histologically by the presence of closely packed tubules of pyloric gland-like epithelium composed of low columnar cells and the characteristic pale or 'ground glass' cytoplasm ( Figure 1A) . Typically, the nuclei of these cells were round and lacked prominent nucleoli. All but one case showed only low-grade dysplasia. Only PGA3 showed focal high-grade dysplasia. Parietal cells between the mucous cells were noted in all PGAs, varying from scattered to abundant, and in some cases were localized very superficially (Figure 1B) . PGA5 showed focal abundance of parietal cells in addition to scattered parietal cells ( Figure 1C ). The histology of PGA3 was particularly remarkable with innumerable parietal cells throughout the polyp, making distinction from oxyntic gland/chief cell adenoma difficult, with numerous intraepithelial lymphocytes and focal high-grade dysplasia ( Figure 1D ,E). Interestingly, the second PGA from this patient (PGA4) showed only scattered parietal cells and had a more classic PGA histology ( Figure 1B) . None of the cases showed atrophy in the background mucosa.
I M M U N O H I S T O C H E M I S T R Y
Immunohistochemistry for MUC2, MUC5, MUC6, CDX2, b-catenin and Ki-67 was performed on five PGAs (Table 2) . Consistent with the existing literature, all PGAs showed MUC6 expression confined mainly to the glandular component (strongly positive in two and focally positive in three PGAs). MUC5A was positive in the foveolar surface epithelium of all polyps (Figure 2A,B) . CDX2 was focally positive in three PGAs and intestinal type MUC2 was negative in all cases. According to the literature, high-grade dysplasia is encountered commonly in sporadic PGAs, but was seen in only one case (PGA3) in the current series ( Figure 1B) . Interestingly, nuclear b-catenin expression was seen only in areas with high-grade dysplasia in PGA3 ( Figure 2C ). All other PGAs showed normal membranous b-catenin expression. Ki-67 was increased significantly only in the areas with highgrade dysplasia in PGA3 and focally in PGA4 of the same patient. The high-grade dysplasia showed positivity for both MUC5 and MUC6. The high-grade dysplasia seen in the first specimen of patient 2 (PGA3) was not seen in the second specimen from this patient (PGA4).
P53 immunohistochemistry was performed only in those PGAs with moderate to high-grade dysplasia (PGA3, PGA4 and PGA5), but showed normal wildtype expression in all cases.
G N A S A N D K R A S M U T A T I O N A N A L Y S I S
Sequencing results are summarized in Table 1 . In all six of six successfully sequenced PGAs, a GNAS mutation was confirmed (100%). A different GNAS mutation was identified in each patient (R201S, R201H and R201C), but patients 2 and 3 showed the same GNAS mutation in PGAs from different time-points. All KRAS mutations were G12V and were seen in three of six PGAs (50%), representing two of three patients (67%). KRAS and GNAS sequencing of PGA1 failed because the lesion was exceedingly small. All FGPs were wild-type for KRAS and GNAS.
Discussion
Pyloric gland adenomas are rare gastric polyps, even in autoimmune gastritis. 9 Recent studies show GNAS and KRAS mutations in sporadic PGAs, but also in FAP-associated PGAs, despite the different background in which these lesions arise. 7 With highly sensitive pyrosequencing this study confirms that FAP-associated PGAs share these distinguishing GNAS mutations with sporadic PGAs, but that FAPassociated FGPs lack these mutations. Nuclear expression of b-catenin was seen in only one case with high-grade dysplasia. TP53 showed normal expression in all stained cases, consistent with previous findings. 4 Our results agree with a previous study of FAP-associated PGAs, showing that sporadic and FAP-associated PGAs have a similar genetic background. 7 Interestingly, over several years, patients 2 and 3 were diagnosed with two and three gastric PGAs, respectively. The first PGA in patient 2 (PGA3) was a 1.5-cm polyp removed with polypectomy. Approximately 2.5 years later, a 0.8-cm PGA was snared (PGA4). The first PGA in patient 3 (PGA5) was a 4-cm PGA removed by polypectomy. Approximately 3.5 years (PGA7) and 5 years (PGA6) after the first polypectomy, gastric biopsies again showed PGAs. Identical GNAS and KRAS mutations were found in the different PGAs from each patient, while the mutations differed between these two patients. Although identical GNAS or KRAS mutations do not provide definitive proof of clonality, it could suggest that these polyps recurred after initial snare polypectomy. Unfortunately, the endoscopy notes do not state whether these polyps arose at the same gastric location as the initial PGAs in these patients. Alternatively, identical mutations can result from clonal expansion of a single transformed cell throughout the stomach (i.e. field cancerization), as suggested previously in a patient with three gastric hyperplastic polyps with identical KRAS mutations. 10 Either way, more radical techniques to remove PGAs and/or close surveillance may be warranted. In this regard, submucosal dissection has been applied successfully to remove a sporadic PGA. 11 However, despite the few cases studied, the rarity of high-grade dysplasia and lack of carcinoma in FAP-associated PGAs, as well as the fact that western FAP patients are not at increased risk of gastric cancer, argue against aggressive treatment of gastric polyps in FAP. 12 In contrast, sporadic PGAs had high-grade dysplasia in 51.2% of cases, approximately 25% of whom also had an associated invasive cancer. This suggests that sporadic lesions may require more aggressive treatment. 1 In contrast to western FAP patients, FAP patients in high-risk areas for gastric cancer such as Japan carry an increased risk of gastric cancer. 13, 14 This increased risk is caused probably by environmental factors adding an extra trigger for tumorigenesis by inflammation, genetic mutations and/or epigenetic alterations. 15 Similarly, the higher incidence of highgrade dysplasia and carcinoma in sporadic PGAs compared to FAP-associated PGAs may be explained by the association of sporadic PGAs with autoimmune atrophic gastritis versus the normal gastric mucosa seen in the background of PGAs in FAP patients. 16 Although we confirmed that sporadic and FAPassociated PGAs have a similar genetic background, we noticed differences in morphology between FAPassociated PGAs and sporadic PGAs. Unfortunately, a direct morphological comparison of sporadic and FAP-associated PGAs could not be performed. However, it is felt that our group is well equipped to compare our findings in PGAs in FAP to the existing literature on sporadic pyloric and oxyntic gland adenomas, as several authors of the current study have contributed significantly to this field. 1, [3] [4] [5] 9, 15, 17, 18 Unfortunately, previous studies on PGAs in FAP did not provide extensive morphological assessment of these polyps. 3, 7 Histopathological examination of FAP associated PGAs in the current series revealed the remarkable presence of parietal cells in all PGAs. The presence of parietal cells varied from scattered to abundant (Figure 1D,E) . Parietal cells have not been reported previously in PGAs, 1, 5 probably because sporadic PGAs arise typically in the background of autoimmune atrophic gastritis, with parietal cells lacking in this condition. In contrast, pyloric gland adenomas in FAP may have a morphology that represents more closely the background mucosa/glandular compartment where the lesion arises. Thus, when a PGA arises in the antrum, the polyp shows predominantly a proliferation of glands lined by mucous cells. However, when a polyp arises in oxyntic mucosa of a FAP patient, the lesion contains glands lined by a mixture of cells normally present at this location, including chief cells and parietal cells.
Some of the PGAs in the current study showed overlapping features with so-called oxyntic gland adenoma (OGA). OGA is another rare gastric polyp characterized by an admixture of gastric cell types with 'predominance of chief cells and scattered parietal cells'. 17 Other terms used previously to address OGA are gastric adenocarcinoma with chief cell differentiation (GA-CCD) or gastric adenocarcinoma of fundic gland type (GAFG). Ueyama et al. subclassified GAFG/OGA into three categories: chief cell predominant type, parietal predominant type and mixed type. 19 A fourth category with predominantly mucous neck cells was suggested by Singhi et al. 17 Indeed, OGA and PGAs are both characterized by MUC6 expression, and GNAS mutations are found in both lesions. 17, [20] [21] [22] Moreover, focal expression of chief cell markers has been shown in eight of 12 PGAs, 21 and we note a variable presence of parietal cells in all PGAs from FAP patients, making differentiation from OGA sometimes extremely difficult or even impossible (for example, PGA3). Based on these observations, and the common GNAS mutations in OGA and PGA, we believe that PGAs may be the fourth category proposed by Singhi et al. 17 OGA and PGA, therefore, seem to be related closely and are probably the same lesions within a spectrum with subtle histological differences, depending on the background mucosa in which they arise.
In contrast to foveolar or intestinal type adenomas, 23 PGA and OGA are caused by a proliferation of the specialized glandular gastric mucosa. To emphasize this key difference in the histogenesis and to uniform terminologies, gastric epithelial polyps may be classified according to the epithelial layer from which the polyp arises ( Table 3 ). The most frequent gastric polyps are fundic gland polyps, arising from the glandular compartment, and hyperplastic polyps arising from the foveolar compartment. 2, 24 Adenomatous polyps arising from the foveolar compartment may or may not have intestinal metaplasia (intestinal type adenoma and gastric foveolar adenoma). The other category of adenomas arises from the glandular compartment and includes PGAs and OGAs. The common denominator is that OGA and PGA are subtypes for which the histology and presence of different specialized glandular cells depends upon the background mucosa wherein the polyp arises. As opposed to gastric foveolar and intestinal type adenomas, 'gastric glandular adenomas' could be an appropriate diagnostic term for such lesions (Table 3 ). This may clarify the diversity of terminologies used currently in the literature for such polyps. In hypertrophic gastritis, a similar subdivision depending on the compartment that has expanded is common practice, with Zollinger-Ellison on one end of the spectrum and M en etrier disease on the other end. 24 To conclude, we confirmed the presence of GNAS and KRAS mutations in pyloric gland adenomas in FAP. Based on morphological findings in FAP-associated PGAs and on existing literature, 17 it is hypothesized that PGAs and OGAs are closely related lesions. Gastric glandular adenomas could be an appropriate unifying diagnostic term for such lesions, which may clarify the current diversity of terminologies for rare gastric polyps.
